Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
Noosa News23 hours agoQantas plane windscreen smashed at Brisbane Airport
-
Noosa News15 hours agoTammy Hembrow’s half-brother walks free after choking and stalking ex-girlfriend
-
Business15 hours agoGuess which ASX 300 stock was downgraded to sell today
-
Noosa News20 hours agoPolice hunt two after baby girl sprayed with stolen fire extinguisher in Sippy Downs